NCT06582199 · RECRUITING
Precision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD
This is an observational study, not a drug test. Researchers will follow 244 people with biologically confirmed mild cognitive impairment or mild Alzheimer's. They will use blood samples and memory and thinking tests to check whether markers of resilience, found in earlier research, hold up. Nobody receives a treatment. There is no phase because nothing is being tested.
You may qualify if
- Diagnosis of AD according to IWG-2 2014 criteria
- Age 50-90 year old
- Affiliated or beneficiary of a social security scheme
- MMSE ≥ 20
- Abnormal CSF Aβ42 or Aβ40/Aβ42 ratio according to local cut-offs
- Abnormal CSF phosphorylated and total Tau according to local cut-offs
- Ability to pass neuropsychological assessments
- Availability of a brain MRI with T1 volumetric sequence performed within 1 year
You're excluded if
- Other cause of dementia
- Participation in an AD therapeutic clinical trial
- Protected adults (including individual under guardianship by court order),
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-03-27